All In Biotech

Drug Trial Radar · NCT03927716

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum

Last checked: Nov 19, 2026Latest source record: Dec 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

352

Actual

Start

Jun 3, 2019

Primary completion

Oct 28, 2019

Study completion Jan 29, 2020

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
Collaborators
Synteract, Inc.
First posted
Apr 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.

Conditions

  • Molluscum Contagiosum

Interventions

  • SB206 12%Drug

    Topically once daily

  • PlaceboDrug

    Topically once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Clearance of All Treatable MC at Week 12Time frame: 12 Weeks

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Site #218

    Mobile, Alabama

  • Site #312

    Glendale, Arizona

  • Site #298

    Little Rock, Arkansas

  • Site #272

    Rogers, Arkansas

  • Site #140

    Lomita, California

  • Site #287

    Boca Raton, Florida

  • Site #303

    Jacksonville, Florida

  • Site #264

    Miami, Florida

  • Site #286

    Miami Lakes, Florida

  • Site #273

    West Palm Beach, Florida

  • Site #116

    Newnan, Georgia

  • Site #302

    Boise, Idaho

  • Site #280

    Chicago, Illinois

  • Site #288

    Evansville, Indiana

  • Site #251

    Indianapolis, Indiana

  • Site #117

    Louisville, Kentucky

  • Site #289

    Metairie, Louisiana

  • Site #219

    Monroe, Louisiana

  • Site #308

    Silver Spring, Maryland

  • Site #296

    Beverly, Massachusetts

  • Site #243

    Clinton Township, Michigan

  • Site #279

    Greensboro, North Carolina

  • Site #270

    Dublin, Ohio

  • Site #252

    Norman, Oklahoma

  • Site #237

    Gresham, Oregon

  • Site #311

    Warwick, Rhode Island

  • Site #259

    Charleston, South Carolina

  • Site #295

    Fountain Inn, South Carolina

  • Site #291

    Kingsport, Tennessee

  • Site #183

    Austin, Texas

  • Site #269

    Katy, Texas

  • Site #299

    Longview, Texas

  • Site #224

    San Antonio, Texas

  • Site #277

    Salt Lake City, Utah

  • Site #285

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.